Results of the 2016 Annual General Meeting
April 28, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland at 11.30am today, all resolutions contained in the Notice of Meeting were decided by poll vote. The results of the poll are as follows:
| Resolutions | For (including discretionary votes) | % | Against | % | Votes cast as a % of relevant shares in issue | Withheld |
| Ordinary Resolutions | ||||||
| 1. To receive the Company's Annual Report and Accounts for the year ended December 31, 2015. | 470,025,424 | 98.71% | 6,142,245 | 1.29% | 80.26% | 291,113 |
| 2. To approve the Directors' Remuneration Report. | 235,249,661 | 50.55% | 230,154,350 | 49.45% | 78.45% | 11,054,771 |
| 3. To re-elect Dominic Blakemore as a Director. | 470,121,989 | 98.70% | 6,207,408 | 1.30% | 80.29% | 129,385 |
| 4. To elect Olivier Bohuon as a Director. | 466,427,485 | 97.92% | 9,905,128 | 2.08% | 80.29% | 126,169 |
| 5. To re-elect William Burns as a Director. | 470,549,161 | 98.79% | 5,783,700 | 1.21% | 80.29% | 125,921 |
| 6. To re-elect Dr. Steven Gillis as a Director. | 468,848,644 | 98.43% | 7,483,905 | 1.57% | 80.29% | 126,233 |
| 7. To re-elect Dr. David Ginsburg as a Director. | 474,415,296 | 99.60% | 1,917,736 | 0.40% | 80.29% | 125,750 |
| 8. To re-elect Susan Kilsby as a Director. | 463,855,077 | 97.38% | 12,478,702 | 2.62% | 80.29% | 125,003 |
| 9. To elect Sara Mathew as a Director. | 469,790,821 | 98.63% | 6,542,652 | 1.37% | 80.29% | 125,309 |
| 10. To re-elect Anne Minto as a Director. | 466,021,105 | 98.89% | 5,252,483 | 1.11% | 79.44% | 5,185,194 |
| 11. To re-elect Dr. Flemming Ornskov as a Director. | 474,415,807 | 99.60% | 1,919,364 | 0.40% | 80.29% | 123,611 |
| 12. To elect Jeffrey Poulton as a Director. | 470,866,225 | 98.85% | 5,468,257 | 1.15% | 80.29% | 124,300 |
| 13. To re-appoint Deloitte LLP as the Company's Auditor. | 454,250,728 | 96.38% | 17,054,940 | 3.62% | 79.44% | 5,153,114 |
| 14. To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor. | 462,464,490 | 97.53% | 11,710,617 | 2.47% | 79.93% | 2,283,675 |
| 15. To authorize the allotment of shares. | 440,997,344 | 92.79% | 34,255,367 | 7.21% | 80.11% | 1,206,071 |
| Special Resolutions | ||||||
| 16. To authorize the disapplication of pre-emption rights. | 446,395,797 | 94.39% | 26,542,021 | 5.61% | 79.72% | 3,520,964 |
| 17. To authorize purchases of own shares. | 470,214,310 | 98.72% | 6,115,636 | 1.28% | 80.29% | 128,836 |
| 18. To increase the authorized share capital. | 465,305,718 | 97.69% | 11,024,146 | 2.31% | 80.29% | 128,918 |
| 19. To adopt new Articles of Association. | 451,403,800 | 97.16% | 13,173,422 | 2.84% | 78.31% | 11,881,560 |
| 20. To approve the notice period for general meetings. | 429,265,355 | 90.61% | 44,462,801 | 9.39% | 79.85% | 2,730,626 |
The Board is pleased to have secured the support of our shareholders for all resolutions. We have engaged extensively with our major shareholders on the remuneration report and acknowledge the vote today. We remain firmly committed to a constructive and appropriate dialogue to fully understand shareholder views as we compete in a global market place.
As at the record date, April 26, 2016, the Company had 593,249,631 Ordinary Shares of 5 pence each in issue (excluding shares held in treasury). Shareholders are entitled to one vote per share. A vote "withheld" is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.
In accordance with Listing Rule 9.6.2R copies of the relevant resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
